**Financial AssiStance to Support the Australian Medical Research and Innovation Priorities 2016‑2018**

Contents

[1 Purpose of this report 3](#_Toc5785656)

[2 Background 4](#_Toc5785657)

[2.1 The Australian Medical Research and Innovation Strategy 4](#_Toc5785658)

[2.2 The Australian Medical Research and Innovation Priorities 4](#_Toc5785659)

[3 Consistency of financial assistance with the 2016‑2018 Priorities 5](#_Toc5785660)

[3.1 Financial assistance provided from the MRFF Special Account 6](#_Toc5785661)

[4 Processes for determining grants of financial assistance 8](#_Toc5785662)

[4.1 Determination of MRFF initiatives 8](#_Toc5785663)

[4.2 Determination of grants of financial assistance 8](#_Toc5785664)

[5 Other financial assistance provided by the Commonwealth 9](#_Toc5785665)

[Appendix A Australian Medical Research and Innovation Priorities 2016‑2018 10](#_Toc5785666)

[Appendix B Initiatives under the 2016‑2018 Priorities 12](#_Toc5785667)

[Appendix C MRFF Grants Awarded from November 2016 to November 2018, by project 14](#_Toc5785668)

[Appendix D MRFF Grants Awarded from November 2016 to November 2018, by initiative 22](#_Toc5785669)

# Purpose of this report

The *Medical Research Future Fund Act 2015* (the MRFF Act) requires the Minister for Health to report to Parliament on the financial assistance provided for medical research and medical innovation from the Medical Research Future Fund Special Account (the MRFF Special Account) during the period the most recent Australian Medical Research and Innovation Priorities were in force.

Accordingly, this report presents the financial assistance provided from the MRFF Special Account during the period that the *Australian Medical Research and Innovation Priorities 2016-2018* (2016-2018 Priorities) were active, specifically from November 2016 until November 2018.

As required under the MRFF Act, this report presents:

* a description of how the financial assistance provided was consistent with the 2016‑2018 Priorities;
* a description of the processes for determining the grants of financial assistance; and
* information about any other financial assistance provided by the Commonwealth for medical research and medical innovation.

# Background

The MRFF Act establishes the independent Australian Medical Research Advisory Board (AMRAB) to determine the:

* Australian Medical Research and Innovation Strategy (the Strategy) every five years.
* Australian Medical Research and Innovation Priorities (the Priorities) every two years.

The MRFF Act requires the Minister to take the Priorities into account when making decisions in relation to the financial assistance provided from the MRFF Special Account.

## The Australian Medical Research and Innovation Strategy

AMRAB developed the Strategy in 2016 following extensive public consultation. The Strategy will be in place for five years as required under the MRFF Act. The intent of the Strategy is:

“*Through strategic investment, to transform health and medical research and innovation to improve lives, build the economy and contribute to health system sustainability*.”[[1]](#footnote-1)

The 2016-2021 Strategy identifies six strategic platforms that serve as a framework for the two-yearly identification of the Priorities:

1. Strategic and international horizons;
2. Data and infrastructure;
3. Health services and systems;
4. Capacity and collaboration;
5. Trials and translation; and
6. Commercialisation.

## The Australian Medical Research and Innovation Priorities

As required by the MRFF Act, AMRAB is responsible for establishing the Priorities to support the MRFF, with each set of Priorities being in force for a two-year period.

The Priorities must be consistent, and align with the vision and strategic platforms that are outlined in the Strategy that is currently in force. Both the MRFF Strategy and Priorities are informed by national consultation as required under the MRFF Act.

# Consistency of financial assistance with the 2016‑2018 Priorities

MRFF initiatives are determined by Government taking into consideration the current MRFF Priorities at the time of commitment. Refer to Appendix A for the 2016-2018 Priorities.

Table 1 presents how MRFF initiatives (as at November 2018) relate to the MRFF strategic platforms and 2016‑2018 Priorities.

Table 1 | Mapping of MRFF initiatives to the current MRFF Strategy and 2016‑2018 Priorities

| **Strategic Platforms** | **2016-2018 Priorities** | **MRFF INITIATIVES\*** |
| --- | --- | --- |
| Strategic and international horizons | Antimicrobial resistance | **Tackling Antimicrobial Resistance** |
| International collaborative research | **International Clinical Trial Collaborations** |
| Disruptive technology | **Frontier Health and Medical Research**  **Genomics Health Futures Mission** |
| Data and infrastructure | Clinical quality registries | *Refer to* **Lifting Clinical Trial and Registry Capacity**^ - Clinical Trial Networks Capacity |
| National data management study | *Associated work occurred in the context of developing the data and analytics stream of the Genomics Health Futures Mission* |
| MRFF infrastructure and evaluation | *Addressed outside of the MRFF with the Government’s commitment of $20 million over four years to support AMRAB activities and program oversight.* |
| Communicable disease control | **National Security Against Pandemic Risk** |
| Health services and systems | National Institute of Research | - |
| Building evidence in primary care | **Keeping Australians out of Hospital**  **Maternal Health and the First 2,000 Days**  **Targeted Health System and Community Organisation Research** |
| Behavioural economics application | **Boosting Preventive Health Research** |
| Drug effectiveness and repurposing | *Captured in part under the intent of the Australian Brain Cancer Mission, Genomics Health Futures Mission and Lifting Clinical Trial and Registry Capacity.* |
| Capacity and collaboration | National infrastructure sharing scheme | *Potential reference to Government announcements around the National Research Infrastructure Roadmap and Lifting Clinical Trial and Registry Capacity.* |
| Industry exchange fellowships | **Industry Researcher Exchange and Training** |
| Clinical researcher fellowships | **Next Generation Clinical Researchers** |
| Trials and translation | Clinical trial network | **Lifting Clinical Trial and Registry Capacity** - Clinical Trial Networks Capacity |
| Public good demonstration trials | **Lifting Clinical Trial and Registry Capacity** - Rare Cancers, Rare Disease and Unmet Need  **Accelerated Research**  **Australian Brain Cancer Mission**  **Million Minds Mental Health Research Mission** |
| Targeted translation topics | **Rapid Applied Research Translation** |
| Commercialisation | Research incubator hubs | **Biomedical Translation Bridge**  **Targeted Translation Research Accelerator** |
| Biomedical translation | **BioMedTech Horizons** |

\*NOTE: ‘MRFF Initiatives’ have been organised by primary priority alignment, appreciating that some initiatives address a number of priorities and where relevant this has been notated. Some priorities have been overtaken by policies, programs and agendas outside of the MRFF.

^ Between the years 2016-17 and 2017-18 the Government transition the name of the Lifting Clinical Trial and Registry capacity initiative to the Clinical Trial Activity: Rare Cancers, Rare Diseases and Unmet Need initiative.

## Financial assistance provided from the MRFF Special Account

Appendix B presents a description of each of these initiatives.

Table 2 presents the funding profiles of the MRFF initiatives as at November 2018.

Table 2 | Funding for Initiatives under the 2016-2018 Priorities as of November 2018

| Initiative | **Actual ($m)** | | **Budget ($m)** | | | | | |  | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 16-17 | 17-18 | 18-19 | 19-20 | 20-21 | 21-22 | 22-23 | 23-24 | 8 Year Total | Out Years | Total |
| Tackling Antimicrobial Resistance |  | 0.5 | 1.8 | 2.2 | 1.2 | 0.3 |  |  | **5.9** |  | **5.9** |
| International Clinical Trial Collaborations |  |  | 4.2 | 12.6 | 12.6 | 12.6 |  |  | **42.0** |  | **42.0** |
| Frontier Health and Medical Research |  |  |  | 40.0 | 60.0 | 60.0 | 60.0 | 20.0 | **240.0** |  | **240.0** |
| Genomics Health Futures Mission |  |  |  |  |  |  |  |  |  |  | **500.0** |
| Australian Brain Cancer Mission |  | 1.0 | 9.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | **35.0** | 15.0 | **50.0** |
| Clinical Trials Activity (Lifting Clinical Trials and Registries capacity and Rare Cancer, Rare Diseases and Unmet needs) |  | 3.3 | 36.7 | 53.5 | 53.9 | 50.0 | 9.2 | 12.4 | **219.0** |  | **219.0** |
| Clinical Trials Network Capacity | 1.0 | 1.5 | 1.5 | 1.0 |  |  |  |  | **5.0** |  | **5.0** |
| Million Minds Mental Health Research Mission |  |  | 5.0 | 5.0 | 15.0 | 15.0 | 25.0 | 15.0 | **80.0** | 45.0 | **125.0** |
| National Security Against Pandemic Risk |  | 2.0 |  |  |  |  |  |  | **2.0** |  | **2.0** |
| Accelerated Research | 7.0 |  | 13.2 | 11.5 | 10.4 | 14.0 |  |  | **56.0** |  | **56.0** |
| Boosting Preventive Health Research | 10.0 |  |  |  |  |  |  |  | **10.0** |  | **10.0** |
| Keeping Australians Out of Hospital |  |  | 9.0 | 4.5 | 4.6 |  |  |  | **18.1** |  | **18.1** |
| Maternal Health and First 2,000 Days |  |  |  | 7.5 | 5.0 | 5.0 |  |  | **17.5** |  | **17.5** |
| Targeted Health System and Community Organisation Research |  |  | 9.8 | 10.0 | 20.0 |  |  |  | **39.8** |  | **39.8** |
| Researcher Exchange and Development Within Industry |  |  |  | 8.0 | 10.0 | 10.0 | 4.0 |  | **32.0** |  | **32.0** |
| Next Generation Clinical Researchers |  | 1.8 | 4.3 | 21.8 | 22.6 | 10.0 | 10.0 | 7.5 | **78.0** |  | **78.0** |
| Rapid Applied Research Translation |  | 10.0 | 20.0 | 20.0 | 20.0 | 15.0 |  |  | **85.0** |  | **85.0** |
| Biomedical Translation Bridge |  |  | 10.4 | 5.3 | 5.3 | 1.3 |  |  | **22.3** |  | **22.3** |
| Targeted Translation Research Accelerator |  |  |  | 6.5 | 12.5 | 12.5 | 15.5 | 15.5 | **62.5** | 62.5 | **125.0** |
| BioMedTech Horizons |  | 10.0 | 5.0 | 10.0 | 20.0 |  |  |  | **45.0** |  | **45.0** |
| **Total** | **18.0** | **30.1** | **138.7** | **281.0** | **346.8** | **280.6** | **183.6** | **125.4** | **1,404.0** | **313.7** | **1,217.6** |

# Processes for determining grants of financial assistance

MRFF initiatives agreed to by Government are designed inclusive of grant opportunities. All MRFF grant opportunities have been conducted consistent with the *Public Governance and Performance Accountability Act 2013*, associated *Commonwealth Grant Rules and Guidelines 2017* (CGRGs) and the MRFF Act. The outcome of these grant opportunities identify the individual grant recipients.

## Determination of MRFF initiatives

AMRAB is responsible for developing the MRFF Strategy and Priorities. The 2016-2021 Strategy and the 2016-2018 Priorities were determined by AMRAB through extensive national consultation with consumers, researchers, healthcare providers and managers.

The Minister for Health must take into account the MRFF Priorities when determining MRFF initiatives.

## Determination of grants of financial assistance

Consistent with the CGRGs, grant opportunities under MRFF initiatives are supported by grant opportunity guidelines and processes that outline the conduct of the application process, assessment of applications, determination of outcomes based on assessment, and awarding of grants to successful applicants.

The Department of Health utilises the Business Grants Hub within the Department of Industry, Innovation and Science, the Community Grants Hub managed by the Department of Social Services and the National Health and Medical Research Council (NHMRC) as grant administrators of MRFF initiatives. In this relationship the Department of Health retains responsibility for policy and program oversight to ensure that grants are meeting the objectives of specific MRFF initiatives. The grant hubs are responsible for conducting the grant opportunity, inclusive of the assessment and delivering a merit assessment to the Program Delegate as determined by the Minister for Health.

Grant opportunities can be open or targeted, the appropriateness of which is dependent on the objectives of the specific initiative. The MRFF Funding Principles endorsed by the Government in October 2017, encourage open and contestable, peer reviewed grant opportunities wherever possible as a means to ensure investment in research excellence. Grant hubs have capacity to deploy an assessment process that involves scientific peer review and relevant perspectives (i.e., from consumers, industry, clinicians) to assist in deliberations.

The list of grant recipients by MRFF initiatives, announced and awarded or under negotiation during the period when the 2016‑2018 Priorities were in force, is provided at Appendices C and D.

# Other financial assistance provided by the Commonwealth

Other financial assistance provided by the Commonwealth for medical research and innovation consists of research grants provided by the NHMRC, funding provided by the Biomedical Translation Fund (BTF) to private sector fund managers to develop and commercialise biomedical discoveries in Australia, as well as funding for a number of other initiatives.

Table 3 outlines the financial assistance provided in 2016‑17 and 2017‑18 (as these are the financial years that have come to an end and are covered by the 2016‑2018 Priorities).

Table 3 | Commonwealth financial support for medical research and innovation ($m)

|  |  |  |
| --- | --- | --- |
|  | **2016-2017**  **($m)** | **2017-2018**  **($m)** |
| NHMRC Research Grants1 | 817.9 | 837.3 |
| Biomedical Translation Fund investments2 | 9.74 | 20.13 |
| Other initiatives3 | 101.82 | 88.06 |

1 NHMRC Research grants were the actual amounts paid as per the 2017-18 NHMRC Annual Report page 136

2 Reporting by the administrator of the Biomedical Translation Fund, the Department of Industry, Innovation and Science.

3The amount for other initiatives were derived from Australian Government’s Science, Research and Innovation (SRI) Budget Tables 2018-19 - Health Portfolio Research and Development investment into the Socio-Economic Objective of 'Health', excluding the MRFF, NHMRC and BTF. At the time of tabling, actual figures are available for 2016-17 and estimated actuals for 2017-18.

1. Australian Medical Research and Innovation Priorities 2016‑2018

The 2016-2018 Australian Medical Research and Innovation Priorities are presented in Table 4 against each of the six platforms of the Australian Medical Research and Innovation Strategy 2016-2021.

Table 4 | Australian Medical Research and Innovation Priorities 2016-18[[2]](#footnote-2)

|  |  |
| --- | --- |
| Priority | Description |
| Strategic and international horizons | |
| **Antimicrobial resistance** | Investment in this global challenge, consistent with Australia’s First National Antimicrobial Resistance Strategy (2015–2019), with a focus on research to bring to market point-of-care solutions |
| **International collaborative research** | Create a reserve for rapid funding of international collaborative work in priority areas of health and medical research, capable of leveraging multiple agency, discipline, national or industry investment. |
| **Disruptive technology** | Assess the impact of disruptive technologies such as artificial intelligence, wearables, genomic engineering and emerging markets on health service delivery and health training requirements. |
| Data and infrastructure | |
| **Clinical quality registries** | Provide start-up investment in disease or therapy-focussed clinical registries supported by a national framework to maximise interoperability and value of research to clinical practice. |
| **National data management study** | Study, in collaboration with key agencies, the requirements for infrastructure enhancement that expands the use of secure, digitised (My Health Record) and linked health and social data and inter-agency collaborative research. |
| **MRFF infrastructure and evaluation** | Establish:   1. a consumer-driven health and medical research agenda, 2. a method to guide future MRFF priorities, and 3. the means to measure and report on economic returns from investments. |
| **Communicable disease control** | Enhance and coordinate research on national surveillance of and response to current and emerging infectious diseases and antimicrobial resistance. |
| Health services and systems | |
| **National Institute of Research** | In partnership with the states and territories, determine the feasibility of establishing a national institute focused on health services, and public and preventive health research to facilitate evidence-based and cost-effective healthcare. |
| **Building evidence in primary care** | Work alongside the Medicare Benefits Schedule Review Taskforce to identify interventions with limited supporting evidence that are amenable to randomised control trial investigations, and engage the existing workforce to build capacity. |
| **Behavioural economics application** | Support development of research in applied behavioural economics that concentrates on public and preventive health, with an emphasis on early intervention in mental health, healthy eating and physical activity |
| **Drug effectiveness and repurposing** | Invest in post-clinical effectiveness studies of drugs and other health interventions and support pre‑clinical proposals that identify new uses for existing drugs. |
| Capacity and collaboration | |
| **National infrastructure sharing scheme** | Develop and evaluate a national scheme that enables researchers to locate and access existing high cost infrastructure to maximise hardware use and foster research collaboration. |
| **Industry exchange fellowships** | Connect industry and academia via PhD and postdoctoral fellowships to enable and encourage talent exchange, with the aim of stimulating entrepreneurial and translation capabilities. |
| **Clinical researcher fellowships** | Expand the scope and scale of the existing NHMRC Practitioner Fellowships Scheme to increase engagement of research-focussed clinicians in problem-solving and the translation of research into clinical practice. |
| Trials and translation | |
| **Clinical trial network** | Provide infrastructure support for existing and new national clinical trial networks to enhance innovation, collaboration, clinical research capacity and patient participation. |
| **Public good demonstration trials** | Invest in extension of clinical trials of proven therapies with limited opportunity for further commercial sponsorship to at-risk groups including adolescents and young adults, culturally diverse groups, and people with complex co-morbidities. |
| **Targeted translation topics** | Work with the NHMRC-accredited Advanced Health Research and Translation Centres to deliver research agendas in primary care, acute and sub-acute settings relating to:   * clinical pathways and care transition, * clinical variation, * co-morbidity, and * health inequities in Aboriginal and Torres Strait Islander Australians and other vulnerable populations. |
| Commercialisation | |
| **Research incubator hubs** | Create and evaluate virtual or actual health research incubator hubs that stimulate partnerships across a range of academic, clinician and industry stakeholders to generate early-stage research ideas for diagnostics, devices and molecular therapeutics. |
| **Biomedical translation** | Through the Biomedical Translation Fund, seek out matched private capital to invest via licensed fund managers in pre-clinical to early clinical translation of research of commercial value. |

1. Initiatives under the 2016‑2018 Priorities

The Initiatives under the 2016-18 Priorities are presented in Table 5.

Table 5 | Initiatives under the 2016-18 Priorities

|  |  |  |
| --- | --- | --- |
| # | Initiative | Description |
| 1 | Accelerated Research | The Australian Government is investing in health and medical research to support emerging priorities and fill gaps in research effort. |
| 2 | Biomedical Translation Bridge | The Australian Government is supporting early-stage research discoveries to develop into viable treatments that will change lives and improve healthcare. |
| 3 | BioMedTech Horizons | The Australian Government is supporting researchers and entrepreneurs to help them turn medical discoveries in viable treatments that will change lives and improve healthcare. |
| 4 | Boosting Preventive Health Research | The Australian Government is investing in research to help promote good health practice, prevent disease and keep people out of hospital. |
| 5 | Australian Brain Cancer Mission | Established to double survival rates and improve the quality of life of people living with brain cancer over the next decade. Cancer Australia will coordinate and administer the Mission. |
| 6 | Clinical Trials Activity (Lifting Clinical Trials and Registries capacity and Rare Cancers, Rare Diseases and Unmet needs) | The Australian Government is investing in clinical trials to improve treatments and discover cures for debilitating and deadly rare cancers, rare diseases and areas of unmet need. |
| 7 | Clinical Trials Network Capacity | The Australian Government is working with Clinical Trial Networks to strengthen sector capability, maximise collaboration, embed clinical trial best practice and foster leadership and knowledge exchange. |
| 8 | Frontier Health and Medical Research | The Australian Government is establishing a program to support researchers to push the boundaries to develop new health and medical breakthroughs. |
| 9 | Genomics Health Futures Mission | The Australian Government is investing to help save or transform the lives of more than 200,000 Australians through research into better testing, diagnosis and treatment |
| 10 | National Security Against Pandemic Risk | The Australian Government is investing in a global effort to fund critical research and development gaps for pandemic preparedness and global health security to better protect Australians. |
| 11 | Researcher Exchange and Development Within Industry | The Australian Government is supporting researchers to work with industry to improve career opportunities and support researchers to remain in the sector. |
| 12 | International Clinical Trial Collaborations | The Australian Government is investing in research to drive a new era of better health care and fuel jobs and growth through research. |
| 13 | Keeping Australians out of Hospital | The Australian Government is investing in research to reduce avoidable hospitalisation and improve the prevention and management of chronic and complex health conditions. |
| 14 | Maternal Health and First 2,000 Days/Women’s Health | The Australian Government is investing in research to improve the opportunity for health intervention in the time between a woman's pregnancy and her child's fifth birthday. |
| 15 | Million Minds Mental Health Research Mission | The Australian Government is investing in bold and transformative research to support one million people with mental health issues access new and innovative approaches to prevention, diagnosis, treatment and recovery. |
| 16 | Next Generation Clinical Researchers | The Australian Government is investing in the talent and capacity of Australia's health and medical research workforce. |
| 17 | Rapid Applied Research Translation | The Australian Government is investing in research that delivers solutions to health service problems that directly benefits patients. |
| 18 | Tackling Antimicrobial Resistance | The Australian Government is investing in research to help tackle the threat in aged care facilities, of microorganisms such as bacteria, viruses or parasites becoming resistant to standard medical treatments. |
| 19 | Targeted Health System and Community Organisation Research | The Australian Government is investing in research to compare the effectiveness of health services, address areas of practice with low evidence and explore consumer-driven research. |
| 20 | Targeted Translation Research Accelerator | The Australian Government is investing in research to improve the lives of patients with chronic conditions through new methods of prevention, treatments and cures. |

1. MRFF Grants Awarded from November 2016 to November 2018, by project

The list of grant recipients by MRFF initiatives, announced and awarded during the period when the 2016‑2018 Priorities were in force, are presented in Table 6.

Table 6 | MRFF grant recipients as at November 2018

| **MRFF Initiative** | **Funded Institution** | **Project Name** | **Funding Amount** |
| --- | --- | --- | --- |
| Accelerated Research | Australian Leukaemia and Lymphoma Group, through Teencancer - Canteen (NSW) | Improving the Treatment of Australian Adolescents and Young Adults with Acute Lymphoblastic Leukaemia | $748,769 |
| Accelerated Research | Canteen (NSW) | Support new clinical trials for adolescents and young adults with cancer. | $1,400,000 |
| Accelerated Research | Cerebral Palsy Alliance (NSW) | Funding to drive research to support the treatment of Cerebral Palsy sponsored by the Cerebral Palsy Alliance. Includes a clinical trial to test the validity of the TheraSuit conducted by the Hudson Medical Research Institute. | $2,000,000 |
| Accelerated Research | Cure for MND Foundation (Vic) | Extended investment via Cure4MND Foundation who previously received $2m under the MRFF Accelerated Research program in 2016-17, and prior to that $2.8m as part of a 2016 Coalition Election Commitment. Investment will support clinical trials and related research activities and project continuity. | $6,000,000 |
| Accelerated Research | Cure for MND Foundation (Vic) | Extended investment via Cure4MND Foundation who previously received $2m under the MRFF Accelerated Research program in 2016-17, and prior to that $2.8m as part of a 2016 Coalition Election Commitment. Investment will support clinical trials and related research activities and project continuity. | $2,156,000 |
| Accelerated Research | Epilepsy Foundation (Vic) | Funding for the Epilepsy Foundation to advance research into treatments including a proof-of-concept study to demonstrate how gene therapy can correct SYNGAP mutations to be conducted by the Florey Institute. | $2,000,000 |
| Accelerated Research) | Garvan Institute of Medical Research, through Teencancer - Canteen (NSW) | AYA-MoST: A Molecular Screening and Therapeutics trial for Australian Adolescents and Young Adults with advanced cancer | $950,000 |
| Accelerated Research | Jean Hailes Foundation (VIC) | Investment to support research priorities identified under a National Endometriosis Action Plan. Research is likely to focus on the prevention and treatment of the condition. Awaiting outcome of a 19 February 2018 Endometriosis Roundtable to better understand priorities for investment. | $2,500,000 |
| Accelerated Research | Kids Cancer Centre, Sydney Children’s Hospital Sydney, through Teencancer - Canteen (NSW) | Personalised targeted therapy for adolescent and young adult medulloblastoma patients | $964,883 |
| Accelerated Research | Movember Foundation (VIC) | The Australian Prostate Cancer Research Centres will be funded to build prostate cancer research capacity in Australia. | $6,000,000 |
| Accelerated Research | Peter MacCallum Cancer Centre Victoria Australasian Sarcoma Study Group, through Teencancer - Canteen (NSW) | Ewing Sarcoma Clinical Trials Programme in AYA Population | $930,000 |
| Accelerated Research | Stem Cells Australia (VIC) | Investment in important research projects in the stem cell / generative medicine space where Stem Cells Australia is providing a filter in terms of evaluation of scientific merit and ensuring the appropriate use of the funds. | $3,000,000 |
| Accelerated Research | Stroke Foundation (Vic) | Funding is being utilised to develop the Australia Living Guidelines for Stroke Management and a targeted clinical research investment in stroke recovery for young survivors titled "return to life, return to work". | $2,500,000 |
| Australian Brain Cancer Mission | University of New South Wales | Zero Childhood Cancer - Personalised medicine program for children who have less than a 30% 5 year survival rate | $5,002,023 |
| Australian Brain Cancer Mission | University of Sydney | Cooperative Trials Group for Neuro-Oncology | $2,500,000 |
| Australian Brain Cancer Mission | Monash University | Australian and New Zealand Children's Haematology/ Oncology Group | $2,500,000 |
| Biomedical Translation Bridge | MTP Connect | Grant awarded to MTPConnect, in partnership with BioCurate, UniQuest and the Medical Device Partnering Program. | $22,300,000 |
| BioMedTech Horizons | MTP Connect | BioMedTech Horizons | $10,000,000 |
| Boosting Preventive Health Research | Sax Institute | The Australian Prevention Partnership Centre (TAPPC) | $10,000,000 |
| Genomics Health Futures Mission | Murdoch Children’s Research Institute (leveraging Australian Genomics) | Mackenzie's Mission: The Australian Reproductive Carrier Screening Project | $19,982,540 |
| Genomics Health Futures Mission | University of Sydney (administering for the Children's Medical Research Institute | ProCan: The human cancer proteome project | $10,700,000 |
| Clinical Trials Networks | Australian Clinical Trials Alliance | Strengthening the capacity, efficiency and effectiveness of Clinical trials networks through the Australian Clinical Trial Alliance | $5,000,000 |
| National Security Against Pandemic Risk | Coalition for Epidemic Preparedness Innovations (CEPI) | National Security Against Pandemic Risk project | $2,000,000 |
| Next Generation Clinical Researchers | The University of Adelaide | Sleep apnea and atrial fibrillation | $431,000\* |
| Next Generation Clinical Researchers | Western Sydney Local Health District | Role of Non-Invasive Imaging using Speckle Tracking Echocardiography in the Identification and Treatment of Patients At Risk of Arrhythmias and Consequent Sudden Cardiac Arrest | $431,000\* |
| Next Generation Clinical Researchers | University of Newcastle | Translation of preventive care for chronic disease risk behaviours into community mental health service delivery | $179,118\* |
| Next Generation Clinical Researchers | Monash University | Closing the evidence-practice gap with a highly innovative, patient-centred, decision-support program to guide narcotic use in chronic low back pain | $179,118\* |
| Next Generation Clinical Researchers | University of New South Wales | Pragmatic implementation trial to reduce evidence practice gap in chronic kidney disease and diabetes | $179,118\* |
| Next Generation Clinical Researchers | University of Sydney | The role of cortical dysfunction in Amyotrophic Lateral Sclerosis (ALS) pathophysiology | $585,270 |
| Next Generation Clinical Researchers | University of Western Australia | Maximising health for older Australians | $585,270 |
| Next Generation Clinical Researchers | University of Western Australia | Community-based studies of diabetes and infectious diseases | $585,270 |
| Next Generation Clinical Researchers | University of Queensland | Personalised early detection of melanoma | $577,189 |
| Next Generation Clinical Researchers | University of New South Wales | Determinants of the outcomes from infectious diseases | $577,189 |
| Next Generation Clinical Researchers | University of Sydney | Improving health outcomes for disadvantaged children | $577,189 |
| Next Generation Clinical Researchers | University of New South Wales | Discovery to therapy implementation in acute stroke | $577,189 |
| Next Generation Clinical Researchers | Florey Institute of Neuro-science and Mental Health | Mild traumatic brain injury and the risk of long-term neurodegenerative and neurobehavioural disease | $577,189 |
| Next Generation Clinical Researchers | Monash University | Generating and translating evidence into practice in women’s health and beyond | $494,733 |
| Next Generation Clinical Researchers | University of Queensland | Early diagnosis and treatment of lung cancer | $487,893 |
| Next Generation Clinical Researchers | Monash University | A national cancer outcome strategy | $487,893 |
| Next Generation Clinical Researchers | Baker Heart and Diabetes Institute | Utility of novel exercise imaging to identify sub-clinical cardiovascular disease | $483,404 |
| Next Generation Clinical Researchers | Queensland University of Technology | Embracing digital disruption in hospitals to improve outcomes among vulnerable people | $483,404 |
| Next Generation Clinical Researchers | La Trobe University | Development and implementation of evidence-based stroke rehabilitation | $483,404 |
| Next Generation Clinical Researchers | University of Sydney | Clinical Trials To Improve Outcome of Cancer Patients | $483,404 |
| Next Generation Clinical Researchers | University of Melbourne | Precision medicine for epilepsy and beyond: from discovery to implementation and evaluation | $481,156 |
| Next Generation Clinical Researchers | University of Sydney | Improving diagnosis, treatment and prevention of mitochondrial disease | $481,156 |
| Next Generation Clinical Researchers | University of Western Australia | Translational Research on Malignant Pleural Effusion and Pleural Infection | $481,156 |
| Next Generation Clinical Researchers | University of Melbourne | Elimination of HCV as a Public Health Threat | $481,156 |
| Next Generation Clinical Researchers | University of Melbourne | Precision therapy for neurological diseases | $476,728 |
| Next Generation Clinical Researchers | University of Sydney | Decreasing unnecessary surgery for low back pain | $476,728 |
| Next Generation Clinical Researchers | Monash University | Cognitive Phenotyping and Personalised Treatment for Methamphetamine Addiction | $476,728 |
| Next Generation Clinical Researchers | University of New South Wales | Understanding and optimising the delivery of chronic disease care for better cardiovascular outcomes | $476,728 |
| Next Generation Clinical Researchers | Murdoch Children’s Research Institute | Significance of low-level mosaicism to intellectual disability in paediatric disorders | $476,728 |
| Next Generation Clinical Researchers | Burnet Institute | Advancing diagnostics and vaccines for malaria elimination | $437,036 |
| Next Generation Clinical Researchers | Monash University | Novel targeted onco-theranostic nanoparticles for personalised therapy and real-time monitoring | $431,000 |
| Next Generation Clinical Researchers | University of Western Australia | Nutritional strategies for allergy prevention | $431,000 |
| Next Generation Clinical Researchers | University of Melbourne | Neuroimaging in mental health: the quest for clinically useful biomarkers | $431,000 |
| Next Generation Clinical Researchers | University of New South Wales | Improving internet-delivered psychological therapies for depression and anxiety | $431,000 |
| Next Generation Clinical Researchers | Murdoch Children’s Research Institute | Improving upper limb function in Hereditary Cerebellar Ataxia | $431,000 |
| Next Generation Clinical Researchers | University of Tasmania | Improving musculoskeletal pain by matching the right treatment with the right patient | $431,000 |
| Next Generation Clinical Researchers | Monash University | Improving outcomes in low back pain: Targeting specific therapies to patient subgroups | $429,055 |
| Next Generation Clinical Researchers | Walter and Eliza Hall Institute of Medical Research | Translational research to drive improved diagnosis and treatment of inflammatory diseases | $418,050 |
| Next Generation Clinical Researchers | University of Sydney | New approaches for treatment of alcohol use disorder | $418,050 |
| Next Generation Clinical Researchers | Monash University | Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia | $412,419 |
| Next Generation Clinical Researchers | Monash University | Improving outcomes for critically ill patients after traumatic brain injury and blood transfusion | $412,278 |
| Next Generation Clinical Researchers | Monash University | Optimising Emergency and Trauma Systems through evidence based pathways | $412,278 |
| Next Generation Clinical Researchers | University of Melbourne | Complex depression and anxiety in youth: Innovative e-therapy and biotherapy clinical trials | $349,629 |
| Next Generation Clinical Researchers | University of Queensland | Improving paediatric critical care outcome | $348,495 |
| Next Generation Clinical Researchers | Garvan Institute of Medical Research | Improving outcomes in osteoporosis and bone health | $343,683 |
| Next Generation Clinical Researchers | Murdoch Children’s Research Institute | Improving the health and development of high risk preterm newborns | $333,710 |
| Next Generation Clinical Researchers | University of Melbourne | Optimising interventions for Staphylococcus aureus and skin infections | $333,710 |
| Next Generation Clinical Researchers | University of Melbourne | Examining new treatments and developing new treatment biomarkers for youth with severe depression | $333,710 |
| Next Generation Clinical Researchers | University of Melbourne | Optimising Respiratory Therapies to Improve Outcomes for Preterm Infants | $305,925 |
| Next Generation Clinical Researchers | University of Sydney | Vaccine safety research in understudied and at risk groups: critical knowledge to inform practice and policy | $286,037 |
| Next Generation Clinical Researchers | The George Institute for Global Health | Sepsis Outcomes Research | $274,946 |
| Next Generation Clinical Researchers | University of Western Australia | Developing personalised treatment for retinal degeneration | $258,600 |
| Next Generation Clinical Researchers | Monash University | Reducing Brain Injury and Improving The Care Of High-Risk Newborn Infants | $241,702 |
| Next Generation Clinical Researchers | Monash University | Next Generation Targeting of DNA-Methylation in Poor Risk Lymphoid Cancer | $218,518 |
| Next Generation Clinical Researchers | Australian National University | Implementation of a peer worker-led mental health recovery program | $179,118 |
| Next Generation Clinical Researchers | University of Wollongong | Implementing a health literacy focused dietetic outpatient model of care for people with chronic kidney disease | $179,118 |
| Next Generation Clinical Researchers | Flinders University of South Australia | Enhancing the capacity of mental health services to review, personalise and intervene early through implementation of real-time outcome monitoring | $179,118 |
| Next Generation Clinical Researchers | University of Tasmania | Sustaining oral and systemic health in Residential Aged Care Facilities | $179,118 |
| Next Generation Clinical Researchers | La Trobe University | Implementing appropriate exercise and education for Australians with knee osteoarthritis | $179,118 |
| Next Generation Clinical Researchers | University of Melbourne | Closing the communication gap in chronic disease | $179,118 |
| Next Generation Clinical Researchers | University of New South Wales | Reducing the burden of dialysis catheter complications - a national approach | $179,118 |
| Next Generation Clinical Researchers | University of New South Wales | Catch them when they fall: Providing best evidence care after a suicide attempt | $179,118 |
| Next Generation Clinical Researchers | Centre for Eye Research Australia Limited | Improving patient management pathways in age-related macular degeneration | $179,118 |
| Rapid Applied Research Translation | Monash University | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18.* | $4,200,783 |
| Rapid Applied Research Translation | Melbourne Academic Centre for Health (MACH) | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $3,900,322 |
| Rapid Applied Research Translation | South Australian Health and Medical Research Institute | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $4,222,222 |
| Rapid Applied Research Translation | Sydney Health Partners | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $4,214,222 |
| Rapid Applied Research Translation | Western Australian Health Translation Network (WAHTN) | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $2,194,222 |
| Rapid Applied Research Translation | Brisbane Diamantina Health Partners | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $2,222,222 |
| Rapid Applied Research Translation | Sydney Partnership for Health Education Research and Enterprise (SPHERE) - University of New South Wales. | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $2,222,222 |
| Rapid Applied Research Translation | Central Australia Academic Health Science Centre | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $2,222,222 |
| Rapid Applied Research Translation | NSW Regional Health Partners | A range of projects have been funded under this initiative guided by the *Australian Medical Research and Innovation Priorities 2016-18*. | $2,222,222 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | The University of Western Australia | BEAT-CF: Bayesian Evidence-Adaptive Trial to optimise management of Cystic Fibrosis | $3,545,905 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Queensland | A platform clinical trial approach to the management of Mycobacterium abscessus complex (MABSC) | $2,091,178 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Sydney | A randomised controlled trial, of N-Acetyl Cysteine, for premanifest Huntington gene expansion carriers (NAC-preHD) | $1,905,227 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | University of Melbourne | Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC) | $1,812,005 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Monash University | The DIAAMOND study: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset | $1,750,726 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | Monash University | Improving survival in myelofibrosis | $1,733,327 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | Monash University | Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study | $1,682,836 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | La Trobe University / Olivia Newton-John Cancer Research | A Basket Study of Low Survival Cancers Treated with EGFR-ADCs | $1,658,626 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Queensland | An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies | $1,642,389 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Monash University | CAST – A Randomised Phase 3 Trial of Cyclophosphamide after Sibling Allogeneic Haematopoietic Stem Cell Transplant | $1,570,198 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | La Trobe University | Prospective, multicentre trial evaluating FET-PET in high grade glioma | $1,564,188 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | University of Sydney | mFOLFIRINOX and STEreotactic body radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG) | $1,512,808 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Monash University | A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukaemia (AML) | $1,507,785 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of New South Wales | Immunotherapy Targeting of Cytomegalovirus antigens in Glioblastoma: INTERROGATE-GBM | $1,446,002 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Queensland | Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer | $1,363,040 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Melbourne | STOP-MSU: Stopping haemorrhage with Tranexamic acid commenced Prehospital in a Mobile Stroke Unit | $1,285,820 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Murdoch Children’s Research Institute | The efficacy of rehabilitation for hereditary ataxias- a randomised controlled trial | $1,227,418 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | The University of Adelaide | Treatment of Severe Early Onset Intrahepatic Cholestasis of Pregnancy | $1,191,769 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Sydney | The BEST-Fluids study: Better Evidence for Selecting Transplant Fluids | $1,117,150 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | Monash University | Brain Oxygen Neuromonitoring In Australia And New Zealand Assessment (BONANZA) Trial | $1,084,852 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of New South Wales | CRISTAL: Cluster Randomised Trial of Aspirin versus Low molecular weight heparin for venous thromboembolism prophylaxis in joint replacement surgery, a registry-nested study | $934,848 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Australian National University | A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics. | $887,072 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Monash University | The BLENDER Trial – Blend to Limit Oxygen in ECMO: A randomised Controlled Registry Trial | $753,355 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | University of Melbourne | SpeechAtax: A rated-blinded randomised controlled trial of intensive home-based speech treatment for ataxia | $498,627 |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | Monash University | A collaborative study of the Interfant network (Australian sites): the feasibility, safety and efficacy of the addition of Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged Acute Lymphoblastic Leukaemia (The Blin-fant Study) | $314,772 |
| Tackling Antimicrobial Resistance | Monash University | Stepped-wedge Trial to increase antibiotic Appropriateness in Residential aged care facilities and model Transmission of antimicrobial resistance (The START Research Program) | $1,826,399 |
| Tackling Antimicrobial Resistance | South Australian Medical Research institute | Using metagenomics and the Registry of Ageing South Australians to understand carriage and transmission of antimicrobial resistance in the elderly | $1,731,374 |
| Tackling Antimicrobial Resistance | University of Queensland | Cluster randomised trial of a multimodal intervention to reduce antimicrobial use in residential aged care facilities | $1,199,976 |
| Tackling Antimicrobial Resistance | University of South Australia | Turning antimicrobial resistance in residential aged care inside-out from the patient to facility level | $1,142,252 |
| **Total** | | | **$213,856,845** |

^Grant Connect ID has been provided where available. A Grant Connect ID may not be available for one off/ad hoc grant opportunities, or those involving certain NHMRC processes (e,g, Next Generation Clinical Researchers).

\*Grant acceptance was withdrawn/relinquished/declined and is not included in the totals.

1. MRFF Grants Awarded from November 2016 to November 2018, by initiative

The funding amount by MRFF initiatives, announced and awarded during the period when the 2016‑2018 Priorities were in force, are presented in Table 7.

Table 7 | Funding amount by MRFF initiatives, as at November 2018

|  |  |  |
| --- | --- | --- |
| **MRFF Initiative** | **Funding Amount** | |
| Accelerated Research | $31,149,652 | |
| Australian Brain Cancer Mission | $10,002,023 | |
| Biomedical Translation Bridge | $22,300,000 | |
| BioMedTech Horizons | $10,000,000 | |
| Boosting Preventive Health Research | $10,000,000 | |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd1 | $26,597,469 | |
| Clinical Trial Activity - Rare Cancers, Rare Diseases and Unmet Need Rd2 | $9,484,454 | |
| Clinical Trials Networks | $5,000,000 | |
| Genomics Health Futures Mission | $30,682,540 | |
| National Security Against Pandemic Risk | $2,000,000 | |
| Next Generation Clinical Researchers | $23,120,047 | |
| Rapid Applied Research Translation | $27,620,659 | |
| Tackling Antimicrobial Resistance | $5,900,001 | |
| **Total** | **$213,856,845** |

1. Australian Medical Research Advisory Board, *Australian Medical Research and Innovation Strategy 2016-2021*, 2016, p. 1 [↑](#footnote-ref-1)
2. Medical Research Future Fund, *Australian Medical Research and Innovation Priorities 2016-2018*, 2016 [↑](#footnote-ref-2)